EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study

Joseph Edgar Blais iD, Ralph Kwame Akyea iD, William Harrison iD, Amy Hai Yan Chan iD, Wenfang Zhong iD, Stephen Franklin Weng, Kebede Abera Beyene iD, Wallis C Y Lau iD, Kenneth K C Man iD, Nadeem Qureshi iD, Esther Wai Yin Chan iD, Ian Chi Kei Wong iD und 1 weitere

PLOS Medicine · 03.11.2026 · 23 (11) · e1005012

DOI: 10.1371/journal.pmed.1005012 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS Medicine, online erschienen am 03.11.2026. Verfasst von Joseph Edgar Blais und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Ko…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Cholesterol, LDL, Primary Prevention. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitas 21.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background The cardiovascular and mortality benefits of achieving guideline-recommended concentrations of low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol with statins in primary prevention remain uncertain. Methods and findings In this new-user cohort study, we used electronic healthcare databases from Hong Kong (HK), New Zealand (NZ) and the United Kingdom (UK) to identify 185,237 patients initiating statins between 1 January 2007 and 31 December 2012 (with follow-up to 31 December 2017) without atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Associations between LDL and non-HDL cholesterol measured within 2 years post-initiation with the outcomes of major adverse cardiovascular events (MACE) or all-cause mortality were assessed in landmark analyses using multivariable Cox regression adjusted for age, sex, hypertension, atrial fibrillation, diabetes mellitus, dyslipidaemia, obesity, smoking, alcohol misuse, rheumatoid arthritis, systemic lupus erythematosus and connective tissue disorders, severe mental illness, antihypertensive drugs, antidiabetic drugs, antiplatelet drugs, and anticoagulant drugs. Estimates were pooled using random-effects meta-analysis. At 2 years, LDL cholesterol was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesCholesterol, LDLPrimary PreventionHumansMaleFemaleAgedMiddle AgedCohort StudiesRisk FactorsUnited KingdomNew ZealandHong Kong

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDL

Autor:innen und Institutionen

  • Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  • Precision Healthcare and Drug Safety (PRISM) Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • Medicines Intelligence Research Group, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • GSK R&D Global Headquarters, London, United Kingdom.
  • Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom.
  • Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

ORCID-Profile: Joseph Edgar Blais, Ralph Kwame Akyea, William Harrison, Amy Hai Yan Chan, Wenfang Zhong, Kebede Abera Beyene, Wallis C Y Lau, Kenneth K C Man, Nadeem Qureshi, Esther Wai Yin Chan, Ian Chi Kei Wong, Jeff Harrison

Förderung

  • Universitas 21

Zitieren

APA

Blais, J. E., Akyea, R. K., Harrison, W., Chan, A. H. Y., Zhong, W., Weng, S. F., Beyene, K. A., Lau, W. C. Y., Man, K. K. C., Qureshi, N., Chan, E. W. Y., Wong, I. C. K., & Harrison, J. (2026). Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study. PLOS Medicine, 23(11), e1005012. https://doi.org/10.1371/journal.pmed.1005012

Vancouver

Blais JE, Akyea RK, Harrison W, Chan AHY, Zhong W, Weng SF, et al. Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study. PLOS Medicine. 2026;23(11):e1005012. doi:10.1371/journal.pmed.1005012

BibTeX
@article{Blais2026,
  author = {Blais, Joseph Edgar and Akyea, Ralph Kwame and Harrison, William and Chan, Amy Hai Yan and Zhong, Wenfang and Weng, Stephen Franklin and Beyene, Kebede Abera and Lau, Wallis C Y and Man, Kenneth K C and Qureshi, Nadeem and Chan, Esther Wai Yin and Wong, Ian Chi Kei and Harrison, Jeff},
  title = {Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {e1005012},
  doi = {10.1371/journal.pmed.1005012}
}
Kostenlos starten →